SingHealth and Duke-NUS Graduate Medical School, which form Singapore's largest academic healthcare cluster, are joining a new global research network to accelerate the discovery of treatments and cures. They will be signing a memorandum of understanding with the Eureka Institute for Translational Medicine today.
As part of the Eureka Institute for Translational Medicine, SingHealth and Duke-NUS join an elite group of academic medical institutes from Europe and North America.
Clinician scientists and researchers from the two institutions will gain access to ideas, knowledge, resources and technologies from across the network, driving globally impactful research.
Joining the network will strengthen their capabilities in translational research, so that promising scientific discoveries can be developed into diagnostic tools, treatments and cures for patients.
"Translational Medicine is like a bridge which joins patients to research. It is a two-way bridge, as unmet medical needs inspire research, and research provides new solutions to fight disease. There are very few people worldwide who know how to build this bridge. There is no formal training in this area and no efficient network to catalyse creativity on an international scale. Eureka aims to address these problems innovatively and comprehensively," said Professor Salvatore Albani, President, Eureka Institute for Translational Medicine.
"SingHealth and Duke-NUS will add to the network with their strengths in biomedical research, and as the network's Asia-Pacific hub, with their insights into diseases common in Asia," added Prof Albani.
"This collaboration has come at the right time as SingHealth and Duke-NUS build up our translational and clinical research capabilities, in tandem with the current phase of Singapore's biomedical sciences initiative." said Professor Soo Khee Chee, Deputy Group CEO, Research & Education, SingHealth.
|Contact: Nicole Lim|